Form 4 for RAPP Rapport Therapeutics, Inc.
Accepted 2026-01-05 00:00:00 ET · period of report 2025-12-31 · accession 0001193125-26-002469 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-05 | 2025-12-31 | RAPP | Yeleswaram Krishnaswamy | Chief Development Off | A - Grant | — | +9,000 | 299.8K | +3% | — | |
| 2026-01-05 | 2025-12-31 | RAPP | Yeleswaram Krishnaswamy | Chief Development Off | S - Sale | $30.05 | -2,840 | 297.0K | -0.9% | -$85.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-31 | A | A | 9,000 | — | 299,831 | D | — | — | (F1) On December 4, 2024, the Reporting Person was granted performance-based restricted stock units ("PSUs") subject to the satisfaction of specified performance criteria as of December 31, 2025. The issuers Compensation Committee confirmed that the performance criteria had been met, resulting in the vesting of such PSUs effective December 31, 2025. |
| 2 | Common | Common Stock | 2025-12-31 | S | D | 2,840 | $30.05 | 296,991 | D | — | — |